DelfaGLP-1 Atlas

Lead sponsor

University at Buffalo

11 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

11

Trials led

0

Active

438

Total enrollment

4

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 2
1
Phase 3
6
Phase 4
1
Not applicable
3

Trials by status

Completed
9
Terminated
1
Withdrawn
1

Trials led

Liraglutide In Overweight Patients With Type 1 DiabetesBMI ≥25Ph 3Completed84
Liraglutide in the Treatment of Type 1 Diabetes MellitusHbA1c ≤8.5%Ph 3Completed72
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 DiabetesBMI 20-30not applicableCompleted70
1966BMI 20-40Ph 3Completed69
1974HbA1c ≤8.5%not applicableCompleted43
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus—not applicableCompleted30
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 DiabetesHbA1c ≤11%Ph 3Completed26
Exeantide in Type 2 Diabetes on InsulinBMI ≥30Ph 2Completed24
1981HbA1c ≤10%Ph 4Terminated15
Liraglutide in Adolescents With Type 1 DiabetesHbA1c ≤10%Ph 3Completed5
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 DiabetesBMI ≤95Ph 3Withdrawnnot disclosed